Call for abstracts

Abstracts submitted for presentation at the EORTC-NCI-AACR Symposium will be reviewed by an international panel of experts in the relevant field and will be judged solely on the data provided. The final decision regarding the presentation format of all selected abstracts lies entirely at the discretion of the Scientific Committee.

SUBMIT ABSTRACT

Abstract submission: 13 April – 8 July 2026
Late Breaking Abstract submission: 12-19 October 2026

Abstracts submitted after the stipulated deadline will not be considered.

Authors are strongly advised to submit their abstracts prior to the deadline and avoid any delays that may affect the evaluation of their work.
For any abstract-related queries, please contact: sabien.dehanscutter@eortc.org

Submitting an abstract for the 38th EORTC‑NCI‑AACR Symposium does not constitute registration for the event. If selected for presentation, abstract presenters must register to attend the 38th EORTC‑NCI‑AACR Symposium.

The presenting author will receive the review outcome and the Scientific Committee’s decision by email no later than mid-September 2026.

PLEASE NOTE: Titles will be released in the programme once the authors have been notified of acceptance of abstracts.

Unless they are part of the media programme, embargoed or not consented, all abstracts will be released on 4 November 2026.
All other abstracts will be released on the day of presentation.

ENA 2026 - Abstract illustration

Abstract Topics

  • Angiogenesis and vascular disrupting agents

  • Animal Models

  • Antibody-drug conjugates
  • Apoptosis inducers
  • Artificial Intelligence
  • Biomarkers Assays
  • Cancer Genomics
  • Cellular Therapies
  • Chemoprevention
  • Combination therapies
  • Combinatorial Chemistry
  • Cytotoxics (including Antimetabolites, Anthracyclin, Alkylating agents, Aurora kinases, Polo-like kinase, Toposisomerase inhibitors, Tubulin-binding compounds)
  • DNA Repair Modulation (e.g. PARP, CHK, ATR, ATM)
  • Drug Delivery
  • Drug Design

  • Drug Resistance and Modifiers

  • Drug Screening
  • Epigenetic modulators (HDAC Bromodomain modulators, EZH2)
  • Functional Genomics
  • Immune checkpoints
  • Molecular profiling
  • Molecular Targeted Agents
  • New agents for paediatric oncology
  • New drugs
  • New therapies in immuno-oncology
  • Novel clinical trial design
  • Oncolytic viruses and vaccination
  • Preclinical Models
  • Radiation Interactive Agents
  • Regulatory Affairs
  • Translational Studies
  • Tumour immunology and inflammation

  • Vaccines